莱科在鼠中具有抗氧化,抗炎和抗的作用,这些老鼠患有万科诱导的神经毒性
Hülya Demirkapı Atik1, Orkun Atik2, Recep Aslan1
1Department of Physiology, Faculty of Veterinary Medicine, University of Afyon Kocatepe, Afyonkarahisar, Türkiye.
Basic & clinical pharmacology & toxicology
|July 21, 2025
概括
莱科 (Lyco) 能防止万科 (Vanco) 引起的损伤 (毒性). 这项研究表明,Lyco可降低氧化应激,炎症和亡,提供一种潜在的保护策略来防止Vanco的副作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
- 生物化学 生物化学
背景情况:
- 范科米辛 (Vanco) 是一种关键的抗生素,但其使用受到毒性 (NPT) 的限制.
- 莱科 (Lyco) 具有抗氧化,抗炎和抗丧的特性.
- 调查Lyco对Vanco诱导的NPT的保护作用至关重要.
研究的目的:
- 为了评估Lycopene在鼠标模型中对万科米辛诱导的毒性产生的保护效果.
- 为了确定Lycopene对氧化应激,炎症和亡标志物的影响,这些标志物与万科米辛治疗有关.
主要方法:
- 总共有48只大鼠被分为六组:对照组,莱科 (5和10毫克/公斤),万科米辛和万科米辛+莱科 (5和10毫克/公斤).
- 范科米是通过腹膜内给药7天,而莱科是通过口服给药.
- 评估了功能标志物,氧化应激指标,炎症标志物和与亡相关的蛋白质.
主要成果:
- 范科米辛的使用显著增加了血清肌素,BUN,尿酸和脏脂质过氧化.
- 范科米辛增加了炎症标志物 (NF-κB,TNF-α) 和亡标志物 (p53,Bax),同时降低了抗氧化剂标志物 (GSH,SOD,CAT,GPx).
- 柳治疗,特别是高剂量治疗,改善了这些效应,减少了氧化应激,炎症和亡.
结论:
- 莱科显示出显著的保护作用,防止万科米辛诱导的毒性.
- 百合素通过减轻氧化应激,炎症和亡来减轻损伤.
- 莱科代表了一种有前途的治疗药物,可以预防与万科米辛相关的损伤.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
663
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
23.8K
相关概念视频
Acute Kidney Injury IV: Diagnostic Studies and Prevention
58
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
58
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
